---
title: "Paxlovid (nirmatrelvir; ritonavir) in COVID-19: Dosing and administration questions"
description: "Dosing and administration questions on Paxlovid (nirmatrelvir; ritonavir) in COVID-19, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Dosing, Taking treatment, Treatment duration, and Prescribing. Questions: What is the Paxlovid dose? What is the Paxlovid dose for kidney disease (renal dosing)? Can Paxlovid be used in patients on dialysis? How soon after COVID-19 symptoms should Paxlovid be started? 6 further questions follow. 10 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/paxlovid--covid-19/dosing-and-administration"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Paxlovid (nirmatrelvir; ritonavir) in COVID-19: Dosing and administration questions

Manufacturer: Pfizer Inc  
Prescribing information: [Paxlovid](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599)

Dosing and administration questions that apply to every indication of Paxlovid are on [Paxlovid (nirmatrelvir; ritonavir), all indications: Dosing and administration](https://www.evicenter.com/medical-information/paxlovid/dosing-and-administration).

## Dosing

<a id="paxlovid-dose"></a>

### What is the Paxlovid dose?

> “The recommended dosage for PAXLOVID is 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) with all 3 tablets taken together orally twice daily in the morning and at bedtime for 5 days.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=The%20recommended%20dosage%20for%20PAXLOVID,at%20bedtime%20for%205%20days.)

> “Standard Dose Pack
>
> for patients with no known/suspected renal impairment (eGFR ≥90 mL/min) or mild renal impairment (eGFR ≥60 to <90 mL/min)
>
> Days: 1-5
> Dose: 2 nirmatrelvir 150 mg tablets (300 mg) + 1 ritonavir 100 mg tablet
> Frequency: Twice daily*†”

Source: [PAXLOVID: Dosing, captured 2026-11-13](https://paxlovid.pfizerpro.com/about-paxlovid/dosing#:~:text=Standard%20Dose%20Pack,Frequency%3A%20Twice%20daily%2A%E2%80%A0)

> “†Each dose should be taken approximately 12 hours apart, typically in the morning and at night.”

Source: [PAXLOVID: Dosing, captured 2026-11-13](https://paxlovid.pfizerpro.com/about-paxlovid/dosing#:~:text=%E2%80%A0Each%20dose%20should%20be%20taken,the%20morning%20and%20at%20night.)

<a id="paxlovid-renal-dosing"></a>

### What is the Paxlovid dose for kidney disease (renal dosing)?

> “No dosage adjustment is recommended in patients with mild renal impairment [estimated glomerular filtration rate (eGFR) ≥60 to <90 mL/min].
>
> In patients with moderate renal impairment (eGFR ≥30 to <60 mL/min) or with severe renal impairment (eGFR <30 mL/min) including those requiring hemodialysis, the dosage of PAXLOVID should be reduced as shown in Table 1. PAXLOVID should be administered at approximately the same time each day for 5 days. On days patients with severe renal impairment undergo hemodialysis, the PAXLOVID dose should be administered after hemodialysis [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3), and How Supplied/Storage and Handling (16)].
>
> Table 1: Recommended Dose and Regimen for Patients with Renal Impairment
>
> Abbreviation: eGFR=estimated glomerular filtration rate.
>
> *
> PAXLOVID should be administered at approximately the same time each day for 5 days.
> †
> On days of hemodialysis, the PAXLOVID dose should be administered after hemodialysis.
>
>
>
> Renal Function
>
>
>
> Days of Treatment
>
>
>
> Dose and Dose Frequency*
>
>
>
>
> Moderate renal impairment (eGFR ≥30 to <60 mL/min)
>
>
>
> Days 1-5
>
>
>
> 150 mg nirmatrelvir (one 150 mg tablet) with 100 mg ritonavir (one 100 mg tablet) twice daily
>
>
>
>
> Severe renal impairment (eGFR <30 mL/min) including those requiring hemodialysis†
>
>
>
> Day 1
>
>
>
> 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) once
>
>
>
>
> Days 2-5
>
>
>
> 150 mg nirmatrelvir (one 150 mg tablet) with 100 mg ritonavir (one 100 mg tablet) once daily”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=No%20dosage%20adjustment%20is%20recommended,100%20mg%20tablet%29%20once%20daily)

> “Renal impairment increases nirmatrelvir exposure, which may increase the risk of PAXLOVID adverse reactions.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=Renal%20impairment%20increases%20nirmatrelvir%20exposure%2C,risk%20of%20PAXLOVID%20adverse%20reactions.)

<a id="paxlovid-dialysis"></a>

### Can Paxlovid be used in patients on dialysis?

> “In patients with moderate renal impairment (eGFR ≥30 to <60 mL/min) or with severe renal impairment (eGFR <30 mL/min) including those requiring hemodialysis, the dosage of PAXLOVID should be reduced as shown in Table 1. PAXLOVID should be administered at approximately the same time each day for 5 days. On days patients with severe renal impairment undergo hemodialysis, the PAXLOVID dose should be administered after hemodialysis [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3), and How Supplied/Storage and Handling (16)].”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=In%20patients%20with%20moderate%20renal,How%20Supplied%2FStorage%20and%20Handling%20%2816%29%5D.)

> “Trial C4671028 (EPIC-SRI) was a Phase 1, open-label trial that evaluated the effects of severe renal impairment on the pharmacokinetics, safety, and tolerability of PAXLOVID in non-hospitalized adult participants with COVID-19 and severe renal impairment. A total of 15 subjects with severe renal impairment were enrolled in this trial, with 12 subjects receiving intermittent hemodialysis and 3 subjects not on hemodialysis. Subjects received nirmatrelvir/ritonavir 300 mg/100 mg once on Day 1 followed by nirmatrelvir/ritonavir 150 mg/100 mg once daily from Days 2-5. The safety profile of PAXLOVID in subjects with severe renal impairment, including those requiring hemodialysis, was consistent with the safety profile observed in the Phase 2/3 randomized, placebo-controlled trials.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=Trial%20C4671028%20%28EPIC%2DSRI%29%20was%20a,Phase%202%2F3%20randomized%2C%20placebo%2Dcontrolled%20trials.)

> “During a 4-hour hemodialysis session, approximately 6.9% of nirmatrelvir dose was cleared through dialysis. Hemodialysis clearance was 1.83 L/h.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=During%20a%204%2Dhour%20hemodialysis%20session%2C,Hemodialysis%20clearance%20was%201.83%20L%2Fh.)

<a id="paxlovid-when-to-start"></a>

### How soon after COVID-19 symptoms should Paxlovid be started?

> “The 5-day treatment course of PAXLOVID should be initiated as soon as possible after a diagnosis of COVID-19 has been made, and within 5 days of symptom onset even if baseline COVID-19 symptoms are mild.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=The%205%2Dday%20treatment%20course%20of,baseline%20COVID%2D19%20symptoms%20are%20mild.)

## Taking treatment

<a id="paxlovid-first-dose-time"></a>

### Should the first Paxlovid dose be taken in the morning or evening?

> “Patients should start with their evening dose if they receive their prescription after the morning”

Source: [PAXLOVID: Dosing, captured 2026-11-13](https://paxlovid.pfizerpro.com/about-paxlovid/dosing#:~:text=Patients%20should%20start%20with%20their,their%20prescription%20after%20the%20morning)

> “If you are taking PAXLOVID tablets twice daily (Figure A or Figure B), take your first dose of PAXLOVID in the morning or at bedtime, depending on when you pick up your prescription, or as your healthcare provider tells you to. Take your doses at around the same time each day.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=If%20you%20are%20taking%20PAXLOVID,the%20same%20time%20each%20day.)

<a id="paxlovid-missed-dose"></a>

### What should patients do if they miss a Paxlovid dose?

> “If the patient misses a dose of PAXLOVID within 8 hours of the time it is usually taken, the patient should take it as soon as possible and resume the normal dosing schedule. If the patient misses a dose by more than 8 hours, the patient should not take the missed dose and instead take the next dose at the regularly scheduled time. The patient should not double the dose to make up for a missed dose.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=If%20the%20patient%20misses%20a,up%20for%20a%20missed%20dose.)

<a id="paxlovid-lost-tablet"></a>

### What should a patient do if a Paxlovid tablet is lost?

> “If a patient loses a tablet, they should contact their healthcare provider and/or pharmacist”

Source: [PAXLOVID: Dosing, captured 2026-11-13](https://paxlovid.pfizerpro.com/about-paxlovid/dosing#:~:text=If%20a%20patient%20loses%20a,their%20healthcare%20provider%20and%2For%20pharmacist)

## Treatment duration

<a id="paxlovid-finish-course"></a>

### Should patients finish all 5 days of Paxlovid if they feel better?

> “Completion of the full 5-day treatment course and continued isolation in accordance with public health recommendations are important to maximize viral clearance and minimize transmission of SARS-CoV-2.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=Completion%20of%20the%20full%205%2Dday,and%20minimize%20transmission%20of%20SARS%2DCoV%2D2.)

> “Do not stop taking PAXLOVID without talking to your healthcare provider, even if you feel better.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=Do%20not%20stop%20taking%20PAXLOVID,even%20if%20you%20feel%20better.)

<a id="paxlovid-hospitalized-during-treatment"></a>

### Should Paxlovid be continued if the patient is hospitalized?

> “Should a patient require hospitalization due to severe or critical COVID-19 after starting treatment with PAXLOVID, the patient should complete the full 5-day treatment course per the healthcare provider's discretion.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=Should%20a%20patient%20require%20hospitalization,per%20the%20healthcare%20provider%27s%20discretion.)

## Prescribing

<a id="paxlovid-prescription-writing"></a>

### How should a Paxlovid prescription be written?

> “Prescriptions should specify the numeric dose of each active ingredient within PAXLOVID. Providers should counsel patients about renal dosing instructions [see Patient Counseling Information (17)].”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=with%20Renal%20Impairment-,Prescriptions%20should%20specify%20the%20numeric%20dose%20of%20each%20active%20ingredient,%5Bsee%20Patient%20Counseling%20Information%20%2817%29%5D.)

## Related pages
- [Medical information: Paxlovid (nirmatrelvir; ritonavir): COVID-19](https://www.evicenter.com/medical-information/paxlovid--covid-19)
- [Indication](https://www.evicenter.com/medical-information/paxlovid--covid-19/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/paxlovid--covid-19/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/paxlovid--covid-19/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/paxlovid--covid-19/safety)
- [Specific populations](https://www.evicenter.com/medical-information/paxlovid--covid-19/specific-populations)
- [Storage and supply](https://www.evicenter.com/medical-information/paxlovid--covid-19/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/paxlovid--covid-19/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/paxlovid--covid-19/guidelines)
